Petros Pharmaceuticals (PTPI) has received a staff determination letter from the Nasdaq Stock Market, informing the Company that Nasdaq determined to suspend trading and delist the Company’s common stock from Nasdaq. At the open of trading on Thursday, May 22, 2025, Petros’ securities will be suspended on Nasdaq and are expected to begin trading on the OTC Markets under the ticker “PTPI”.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTPI:
- Petros Pharmaceuticals partners with Innolitics
- Petros Pharmaceuticals strengthens partnership with big data provider
- AI Daily: Microsoft reports earnings, says Cloud, AI ‘essential inputs’
- Petros Pharmaceuticals developing SaaS Platform using AI, EHR
- Petros Pharmaceuticals trading halted, news pending